James W F Catto
Overview
Explore the profile of James W F Catto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
201
Citations
6337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nanton V, Bryan R, Pope A, Hughes A, Jefferson K, Catto J, et al.
BMJ Oncol
. 2025 Jan;
2(1):e000092.
PMID: 39886495
Recruitment and retention in cancer trials are long-standing issues, exacerbated by the COVID-19 pandemic. The UK National Institute of Health Research and leading clinicians have emphasised the urgency to achieve...
2.
Daneshmand S, Kamat A, Shore N, Meeks J, Galsky M, Jacob J, et al.
Urol Oncol
. 2025 Jan;
PMID: 39818460
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review...
3.
Bryan R, Liu W, Pirrie S, Amir R, Gallagher J, Hughes A, et al.
J Clin Oncol
. 2025 Jan;
:JCO2302398.
PMID: 39808757
Purpose: Transurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive treatment. We investigated whether...
4.
Mandrik O, Thomas C, Akpan E, Catto J, Chilcott J
Pharmacoeconomics
. 2025 Jan;
PMID: 39753833
Background: Testing high-risk populations for non-visible haematuria may enable earlier detection of bladder cancer, potentially decreasing mortality. This research aimed to assess the cost-effectiveness of urine dipstick screening for bladder...
5.
Li R, Linscott J, Catto J, Daneshmand S, Faltas B, Kamat A, et al.
Eur Urol
. 2024 Oct;
87(2):110-122.
PMID: 39353825
Background And Objective: The 2024 US Food and Drug Administration approval of erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with FGFR3 alterations ushered in the era of targeted...
6.
Conroy S, Jubber I, Noon A, Rosario D, Griffin J, Morgan S, et al.
BJU Int
. 2024 Sep;
135(2):329-338.
PMID: 39324506
Objective: To report real-world outcomes for high-risk non-muscle-invasive bladder cancer (HRNMIBC), including bacillus Calmette-Guérin (BCG) and radical cystectomy (RC), as randomised comparisons of these have not been possible. Methods: We...
7.
Powles T, Catto J, Galsky M, Al-Ahmadie H, Meeks J, Nishiyama H, et al.
N Engl J Med
. 2024 Sep;
391(19):1773-1786.
PMID: 39282910
Background: Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes. Methods: In this phase 3, open-label,...
8.
Hof J, Vermeulen S, van der Heijden A, Verhaegh G, Dyrskjot L, Catto J, et al.
Bladder Cancer
. 2024 Jul;
9(1):59-71.
PMID: 38994482
Background: Various germline genetic variants are associated with the prognosis of non-muscle invasive bladder cancer (NMIBC). Germline variants in genes frequently somatically mutated in bladder cancer have not been studied...
9.
Absolom K, Rogers Z, Catto J, Bottomley S, Glaser A, Downing A
Eur Urol
. 2024 May;
86(3):286-288.
PMID: 38735822
No abstract available.
10.
Sivakumaar K, Griffin J, Schofield E, Catto J, Jubber I
J Clin Pathol
. 2024 Feb;
77(5):291-296.
PMID: 38418202
Uroplakins are a family of membrane-spanning proteins highly specific to the urothelium. There are four uroplakin proteins in humans. These are encoded by the following genes: , , and Uroplakin...